NASDAQ:CTNM
Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc. reported net income of −$60.0M in fiscal 2025. Free cash flow was −$55.5M, and the diluted share count rose 43.1%.Summary generated from Contineum Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−26.1%
Debt / equityn/a
Free cash flow−$55.5M
FCF marginn/a
Share count change+43.1%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 50 | 0 | n/a |
| Operating income | 16 | −51 | −68 |
| Net income | 23 | −42 | −60 |
| Free cash flow | 19 | −33 | −56 |
Recent filings
- 8-KOther events
Sep 14, 2026 - 4Insider transaction report
Sep 8, 2026 - 4Insider transaction report
Aug 3, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 30, 2026 - 8-KResults of operations and financial condition
Jul 30, 2026 - 8-KRegulation FD disclosure
Jul 13, 2026 - 8-KResults of a shareholder vote
Jun 26, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 5, 2026